Tramway Venture Partners
Overview
Tramway Venture Partners is a venture capital firm that invests in early-stage life science, healthcare, and technology companies in the Southwest of the United States.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Nob Hill Therapeutics | Aug 2024 | Series A | Lead |
| Vitazi.ai | Nov 2022 | Seed | Co-investor |
| WaveFront Dynamics Inc. | Sep 2023 | Series B | Co-investor |
| Breezy Med | Mar 2025 | Strategic | Co-investor |
| Daisy Genomics | Dec 2025 | Seed | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Tramway Venture Partners based?
Tramway Venture Partners is headquartered in Albuquerque, New Mexico, United States.
When was Tramway Venture Partners founded?
Tramway Venture Partners was founded in 2017.
How many portfolio companies does Tramway Venture Partners have?
Tramway Venture Partners has 7 portfolio companies in Caplight's dataset.
What are some companies in Tramway Venture Partners's portfolio?
Portfolio companies visible on Caplight include Nob Hill Therapeutics, Vitazi.ai, WaveFront Dynamics Inc., Breezy Med, Daisy Genomics.
What was Tramway Venture Partners's most recent investment shown here?
Tramway Venture Partners's most recent investment in this portfolio sample was in Daisy Genomics in 2025.
What sectors does Tramway Venture Partners focus on?
Tramway Venture Partners focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure, Frontier & Industrial Tech, Frontier & Industrial Tech, Frontier & Industrial Tech.
What company stages does Tramway Venture Partners focus on?
Tramway Venture Partners typically invests at the Early stage.
What is Tramway Venture Partners's AUM?
Tramway Venture Partners's assets under management are estimated between $15.0M and $55.0M.